PRRT Neuroendocrine Tumor Response monitored using Circulating Transcript Analysis: The NETest

Reliable biomarkers for neuroendocrine tumor (NET) management during peptide receptor radionuclide therapy (PRRT) are lacking. We validated the role of two circulating biomarkers, the PRRT-predictive-quotient (PPQ) as a predictive marker for response and NETest as a monitoring biomarker. Furthermore, we evaluated whether tissue-based genetic alterations were effective in predicting progression-free survival (PFS).